FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Clinical trials for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) explained in plain language.
Never miss a new study
Get alerted when new FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) trials appear
Sign up with your email to follow new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug combo may halt painful bone flares in rare FOP condition
Disease control Recruiting nowThis study looks at whether anti-IL1 medications (like anakinra or canakinumab) can reduce flare-ups and prevent extra bone growth in people with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder where soft tissues turn into bone. About 11 participants with sev…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
Could this pill stop FOP's bone buildup?
Disease control Recruiting nowThis study tests an experimental drug (INCB000928) in people with fibrodysplasia ossificans progressiva (FOP), a rare condition where soft tissues turn into bone. About 98 participants aged 2 and older will receive either the drug or a placebo to see if it reduces new abnormal bo…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
Worldwide FOP database launches to unlock secrets of rare bone disorder
Knowledge-focused Recruiting nowThis study creates a global online registry for people with Fibrodysplasia Ossificans Progressiva (FOP), a rare condition where soft tissues turn into bone. Participants and their doctors can securely report symptoms, flare-ups, and mobility changes over time. The goal is to gath…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Sponsor: The International FOP Association • Aim: Knowledge-focused
Last updated May 17, 2026 02:07 UTC